Affordable Pricing for Taxpayer-Funded Prescription Drugs Act of 2021

Summary

Affordable Pricing for Taxpayer-Funded Prescription Drugs Act of 2021 This bill requires companies that receive federal funding for research (or a license of the rights to a patent or regulatory test data) for a biomedical product or service to agree to set reasonable prices for the resulting biomedical product or service. The Department of Health and Human Services (HHS) must determine a reasonable price based on a formula that ensures the U.S. price for the product or service is not more than the median price for the product or service in Canada and six other reference countries with, based on specified criteria, large economies and high incomes. Companies entering these agreements also must report to HHS certain financial information related to the biomedical product or service involved.

This text is taken from the official record. PoliticalRepo does not editorialize.

Timeline

No timeline events have been ingested for this record yet.

Votes

No vote records are attached yet.

Versions

No version snapshots stored. Document URLs remain at the source.

Documents

3 official files

• Introduced in House (text)

  Introduced in House · EN · 10 August 2021

  ViewDownloadOpen at official source

• Introduced in House (PDF)

  Introduced in House · EN · 10 August 2021

  ViewDownloadOpen at official source

• Introduced in House

  summary · EN · 10 August 2021

  Open at official source

Sponsors

No sponsors or actors listed by the source.

Related records

No cross-record relationships stored yet.